CELLINK announces partnership with MIS to develop advanced bioprinting technology for space

CELLINK today announced its partnership with Made In Space, Inc. (MIS), the industry leader for space manufacturing technologies, to develop advanced bioprinting technology for space. The partnership looks to combine MIS expertise in additive manufacturing in microgravity with CELLINK’s innovative bioprinting technologies and leverage the microgravity environment to gain insights that could improve drug screening and cancer research on Earth.

CELLINK supports space programs in the United States with our deep commitment to cutting-edge innovation, extensive portfolio of technologies and world-class team of scientists and engineers. We are excited to partner with Made In Space to refine bioprinting technologies that can support and enhance future missions in spaceflight and space exploration.”

CELLINK co-founder and CEO Erik Gatenholm

Through this strategic partnership, CELLINK and MIS intend to align their technical competencies and identify technology development opportunities across several pathways including the International Space Station and future platforms.

Bioprinting has the potential to mitigate crew health and safety risks on long-duration spaceflight missions where access to standard medical facilities isn’t readily available. Bioprinting capabilities optimized to operate in the space environment could enable future crews to develop skin and bone patches to aid in wound healing in space.

CELLINK has prior experience in space and worked with the Swedish National Space Agency and Uppsala University to launch bioprinted stem cells on a suborbital flight onboard the MASER 14 vehicle in June 2019.

MIS was founded in 2010 and has pioneered space manufacturing capabilities in space dating back to the first demonstration of additive manufacturing in space in 2014. The company’s mission is to industrialize low-Earth orbit and support future space exploration through on-orbit manufacturing and assembly and materials development.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    CELLINK. (2019, December 17). CELLINK announces partnership with MIS to develop advanced bioprinting technology for space. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/20191217/CELLINK-announces-partnership-with-MIS-to-develop-advanced-bioprinting-technology-for-space.aspx.

  • MLA

    CELLINK. "CELLINK announces partnership with MIS to develop advanced bioprinting technology for space". News-Medical. 22 December 2024. <https://www.news-medical.net/news/20191217/CELLINK-announces-partnership-with-MIS-to-develop-advanced-bioprinting-technology-for-space.aspx>.

  • Chicago

    CELLINK. "CELLINK announces partnership with MIS to develop advanced bioprinting technology for space". News-Medical. https://www.news-medical.net/news/20191217/CELLINK-announces-partnership-with-MIS-to-develop-advanced-bioprinting-technology-for-space.aspx. (accessed December 22, 2024).

  • Harvard

    CELLINK. 2019. CELLINK announces partnership with MIS to develop advanced bioprinting technology for space. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/20191217/CELLINK-announces-partnership-with-MIS-to-develop-advanced-bioprinting-technology-for-space.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CELLINK announces partnership with AstraZeneca to provide advanced 3D-bioprinted liver organoids